FDA declines to approve King's imaging agent

The FDA has declined to approve King Pharmaceuticals' experimental imaging agent CorVue, saying it needs to see more information before it can make a final decision. King (KG) had hoped to win an approval for the imaging agent, which has been tested in assessing the risk of coronary artery disease. Analysts were left guessing just how big a setback this is for King, which didn't specify exactly what the FDA is looking for. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.